A California based molecular diagnostics
company has announced that it has developed a new test kit
for the new 2019-nCoV coronavirus
that can provide results in less than 30 minutes.
Cepheid, a leading biotech and molecular diagnostics
company announced that in response to the rapid outbreak of a new coronavirus
strain, the company has developed an automated molecular test for the qualitative detection of the 2019-nCoV coronavirus
The test will be designed for use on any of its 23,000 GeneXpert®
Systems placed worldwide and is expected to deliver point-of-care results in about less than 30 minutes.
Dr. David Persing, MD, Ph.D., Chief Medical and Technology Officer at Cepheid told Thailand Medical News
, "The emergence of the 2019-nCoV coronavirus
outbreak has put significant pressure on healthcare facilities. An accurate test with a rapid turnaround time delivered close to the patient will expedite diagnostic
testing and help alleviate these pressures.”
He added further, “Over at Cepheid, we have managed to leverage the design principles of our current Xpert® Xpress
Flu/RSV cartridge technology, in which multiple regions of the viral genome are targeted to provide rapid detection of current and future pandemic coronavirus
The company said that as a result of the virus rapidly spreading around the world plus intel collated from various sources that indicates that it is unlikely that the coronavirus
would go away anytime soon, the company invested all its resources and capabilities into developing this new diagnostic test kit.
The biotech and molecular company has a history of responding quickly and working with global health organizations to help manage infectious disease outbreaks, such as Ebola virus and 2009 H1N1 influenza.
Once details are finalized, Cepheid intends to access the FDA's Emergency Use Authorization pathway for regulatory approval and make the test available globally.
Cephied said that providing access to timely, highly accurate diagnostics
that improve patient outcomes and public health worldwide is at the heart of Cepheid's mission.
Considering that time is a critical factor in managing the spread of the
as well as providing fast treatment to the infected as it is now known that for many, once infected with the coronavirus
with initial signs such as fever and cough manifesting, it typically takes about three weeks for the patient’s condition to rapidly progress into a severe critical state.
The company plans to have the test kits commercially available with the next 7 to 14 days.
For latest developments and news about coronavirus research
, the coronavirus epidemic
or the Thailand Coronavirus
scenario, keep on checking at: https://www.thailandmedical.news/articles/coronavirus